PROCEDURE:
Powered by convective water vapor energy, the Rezūm System delivers targeted, controlled doses of the stored thermal energy in water vapor directly to the region of the prostate gland with the obstructive tissue causing the lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
Each 9-second treatment uses 0.42ml of heated sterile water vapor which rapidly and uniformly disperses through the tissue interstices. The condensation of water vapor releases stored thermal energy. Cell membranes are denatured, thereby causing immediate cell death, the vasculature is closed, and there is denervation of the alpha-adrenergic nerves within the treatment zone providing you with an efficient, uniform, predictable treatment.
Over time, this ablated tissue is reabsorbed by the body’s natural healing response, reducing the volume of tissue allowing the urethra to open relieving LUTS.
The Rezūm procedure provides the following benefits to men suffering from BPH:
-
Alternative to BPH medications (1)
-
Studies support Rezūm relieves symptoms safely and effectively (2)
-
Noticeable symptom improvement within two weeks (2)
-
Simple in-office/out-patient therapy (2)
-
Does not require general anesthesia (2)
-
Preserves erectile and urinary functions (2)
-
Ability to return to regular activities within a few days (2*)
-
Covered by Medicare and most private insurers (3**)
Dependent on individual clinical situation and healing response.
**Rezum Calgary does not guarantee insurance coverage for any procedure or product. It is the responsibility of the patient to contact their insurance provider for specific coverage information.
1. McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology Gold Journal. 2019 Jan 23. [Epub ahead of print]
2. McVary KT, Gange SN, Gittelman MC, et al. Minimally invasive prostate convective water vapor energy (WAVE) ablation: A multicenter, randomized, controlled study for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2016; 195: 1529.
3. Data on file with Boston Scientific.
The Rezūm System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with BPH. It is indicated for men ≥ 50 years of age with a prostate volume 30cm3 ≤ 80cm3. The Rezūm System is also indicated for treatment of prostate with hyperplasia of the central zone and/or a median lobe.
Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.
All images are the property of Boston Scientific. All trademarks are the property of their respective owners.
Procedure photos
DEVICE PHOTOS
SCience of Rezum
Combining the Efficiency of Convective Thermal Energy and Anatomy
A hand-held delivery device, similar in shape and size to a cystoscope, is connected to a generator. A few drops of sterile water are heated to approximately 103ºC and as the sterile water is transformed from liquid into steam, or vapor, the volume expands by almost 1,700 times and stores 540 calories of thermal energy for every milliliter (mL).
A precise dose of water vapor thermal energy is delivered into the targeted tissue using a small needle with multiple emitter holes to enable controlled and uniform vapor dispersion. The vapor is delivered into the targeted tissue at slightly above interstitial pressure, convectively driving the water vapor through tissue interstices, where it condenses and transfers the stored thermal energy directly to the targeted tissue. This convective heat transfer is what differentiates Rezūm from other ablative thermal therapies that rely on the slower, less precise and less efficient process of conduction to heat tissue.
Convective transfer of water vapor thermal energy to tissue is fast but also self-limiting. Water vapor condenses back into its liquid state as it is dispersed through tissue, so the energy travels no further than its intended area of treatment. The prostate is comprised of three separate zones or regions and the enlarged tissue that causes BPH is located in two of them – the transition zone and the central zone. The tissue separating these zones provides a natural anatomical barrier that contains the vapor within the intended treatment areas.
The Rezūm System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with BPH. It is indicated for men ≥ 50 years of age with a prostate volume 30cm3 ≤ 80cm3. The Rezūm System is also indicated for treatment of prostate with hyperplasia of the central zone and/or a median lobe.
Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.
All images are the property of Boston Scientific. All trademarks are the property of their respective owners.